Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket

Gainers

• OncoCyte Corporation OCX rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.
• Spruce Biosciences, Inc. SPRB shares rose 84% to $2.30 in pre-market trading. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan.
• CytomX Therapeutics, Inc. CTMX rose 70.4% to $3.05 in pre-market trading. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics.
• AMTD Digital Inc. HKD shares rose 40.2% to $42.00 in pre-market trading after surging around 200% on Thursday.
• Golden Sun Education Group Limited GSUN rose 27% to $1.60 in pre-market trading after jumping around 18% on Thursday.
• Magic Empire Global Limited MEGL rose 25.2% to $2.88 in pre-market trading after climbing 75% on Thursday.
• Mobile Global Esports Inc. MGAM rose 17.8% to $1.26 in pre-market trading after gaining over 21% on Thursday.
• Aethlon Medical, Inc. AEMD shares rose 17.2% to $0.4030 in pre-market trading. Aethlon Medical, last month, posted a Q2 loss of $0.18 per share.
• eFFECTOR Therapeutics, Inc. EFTR rose 14.2% to $0.63 in pre-market trading after the company issued a clinical data update for Zotatifin.
• World Wrestling Entertainment, Inc. WWE rose 9.7% to $79.00 in pre-market trading on the news report that the company could be exploring a potential sale. The Wall Street Journal reported that former chief Vince McMahon plans to return to the company.

Losers

• Graphite Bio, Inc. GRPH fell 50.5% to $1.51 in pre-market trading after the company reported voluntary pause of Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease.
• Fate Therapeutics, Inc. FATE shares fell 49.1% to $5.60 in pre-market trading after the company reported termination of collaboration agreement with Janssen Biotech, Inc.
• Virios Therapeutics, Inc. VIRI fell 27.3% to $0.20 in pre-market trading. Virios Therapeutics announced scheduling of FDA meeting in March 2023 to discuss IMC-1 Fibromyalgia Phase 3 program.
• Acasti Pharma Inc. ACST fell 15.7% to $0.5183 in pre-market trading. Acasti is expected to host conference call on Tuesday, January 10, 2023 to discuss results from recent Phase 1 PK studies for GTX-101 and GTX-102 that met all outcome measures.
• Vyant Bio, Inc. VYNT fell 14.1% to $1.04 in pre-market trading. Vyant Bio shares jumped around 57% on Thursday after the company engaged LifeSci Capital as its advisor to explore strategic alternatives.
• ABVC BioPharma, Inc. ABVC fell 13.5% to $0.9250 in pre-market trading. ABVC BioPharma shares climbed over 72% on Thursday after the company announced the FDA approved its IND submission, allowing the company to proceed with the clinical study of ABV-1519 for the treatment of non-small cell lung cancer.
• Bed Bath & Beyond Inc. BBBY fell 12.4% to $1.48 in pre-market trading after dropping around 30% on Thursday. The company said it will miss its 10-Q filing deadline for the quarter ending Nov 26, 2022 and has also concluded that there is substantial doubt about its ability to continue as a going concern.
• Oblong, Inc. OBLG fell 11.7% to $2.41 in pre-market trading after gaining around 24% on Thursday. Oblong recently announced a 1-for-15 reverse stock split.
• InMed Pharmaceuticals Inc. INM fell 10.8% to $1.72 in pre-market trading after declining over 11% on Thursday.
• Orchard Therapeutics plc ORTX shares fell 9.9% to $0.5674 in pre-market trading. Orchard Therapeutics shares gained around 22% on Thursday after the company announced FDA clearance of the IND application for OTL-203 in MPS-IH.

Read More: Insiders Selling Qualcomm, Skechers And 2 Other Stocks